Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule
PS Linsley, PM Wallace, J Johnson, MG Gibson… - Science, 1992 - science.org
PS Linsley, PM Wallace, J Johnson, MG Gibson, JAL Greene, JA Ledbetter, C Singh…
Science, 1992•science.orgIn vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell
surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is
generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7
with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody
responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig
suppressed responses to a second immunization. Thus, costimulation by B7 is important for …
surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is
generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7
with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody
responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig
suppressed responses to a second immunization. Thus, costimulation by B7 is important for …
In vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is generated. CTLA4Ig is a soluble form of the extracellular domain of CTLA-4 and binds B7 with high avidity. CTLA4Ig treatment in vivo suppressed T cell-dependent antibody responses to sheep erythrocytes or keyhole limpet hemocyanin. Large doses of CTLA4Ig suppressed responses to a second immunization. Thus, costimulation by B7 is important for humoral immune responses in vivo, and interference with costimulation may be useful for treatment of antibody-mediated autoimmune disease.
AAAS